Diabetic retinopathy (DR) is the major ocular complication of diabetes mellitus, and is a
problem with significant global health impact. Major advances in diagnostics, technology …

Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …

Vascular complications of diabetes pose a severe threat to human health. Prevention and
treatment protocols based on a single vascular complication are no longer suitable for the …

Diabetic retinopathy (DR), with increasing incidence, is the major cause of vision loss and
blindness worldwide in working-age adults. Diabetic macular edema (DME) remains the …

Diabetic retinopathy (DR) is a leading cause of visual impairment and blindness worldwide.
Since DR was first recognized as an important complication of diabetes, there have been …

Purpose To evaluate 2-year efficacy, durability, and safety of the bispecific antibody
faricimab, which inhibits both angiopoietin-2 and VEGF-A. Design TENAYA (ClinicalTrials …

Purpose To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and
vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab …

Faricimab (faricimab-svoa; Vabysmo™) is a bispecific antibody that binds to and inhibits
both vascular endothelial growth factor (VEGF)-A and angiopoietin-2 (Ang-2). Administered …

Single-cell analysis in living humans is essential for understanding disease mechanisms,
but it is impractical in non-regenerative organs, such as the eye and brain, because tissue …

Background A high-dose formulation of intravitreal aflibercept (8 mg) could improve
treatment outcomes in diabetic macular oedema (DMO) by requiring fewer injections than …